New Study Suggests Increasing Certain Protein​ in Brain‌ May Help Slow Alzheimer’s Progression

A recent study suggests ⁣that increasing a specific protein in the brain may help slow the​ progression of Alzheimer’s ⁣disease. Researchers at ​the University of Cincinnati⁤ dispute the long-held theory that Alzheimer’s disease‍ occurs when a protein called amyloid beta 42 ⁢(Aβ42) builds up in the brain in the form of plaques, damaging nerve⁢ cells and causing cognitive decline.

Instead, the researchers propose ⁣that⁣ the disease is caused by low levels of healthy, functioning‍ Aβ42. This hypothesis ⁢is based on the fact that newly‌ approved ⁤monoclonal antibody drugs, including lecanemab (Leqembi) and donanemab (Kisunla), unintentionally resulted in‍ increased​ levels of Aβ42 in the⁢ brain.

Understanding the Role of Aβ42 in Alzheimer’s Disease

According to⁣ Dr. Alberto J. Espay, professor of neurology and director of the Gardner Family Center for⁢ Parkinson’s and Movement Disorders at UC, “New Alzheimer’s therapies designed to clear amyloid plaques may ⁣inadvertently increase ‌Aβ42 ⁢levels, which‍ may explain the positive‍ effects on ‌cognition​ as much or more than​ the amyloid reduction.”

Espay also⁢ notes that “higher Aβ42 levels after treatment⁣ were⁢ associated with slower cognitive decline, suggesting that restoring this protein to normal levels may be‌ more beneficial for Alzheimer’s patients than clearing amyloid.”

Study Findings

The study reviewed data from nearly 26,000 Alzheimer’s patients who participated⁣ in 24 randomized clinical trials of newly​ approved ⁤antibody therapies. The researchers compared patients’ cognitive abilities before and after taking the ⁣new drug and found that increased ‌amounts of Aβ42 were associated with “slower progression of cognitive impairment and clinical decline.”

Challenging Long-Held Beliefs

The study challenges long-held beliefs that amyloid plaques are the direct cause of Alzheimer’s disease and that‌ removing them is part of the solution. Instead, the researchers suggest that amyloid plaques may be a response to stressors in‌ the brain and that increasing Aβ42 levels without clearing amyloid ‍may be a potential treatment for ⁢the disease.

A Complex Disease

Dr. Ojama Ismail, director of scientific programs at the Alzheimer’s Association in Washington, ‍D.C., notes ⁤that “while the Aβ42 hypothesis may turn out to be part of‌ the cause ⁢and progression of Alzheimer’s disease, ​it is a⁢ very ‍complex disease, and most researchers ⁢do not believe that Alzheimer’s disease is caused by a single ⁤biological mechanism.”

Ismail recommends a ​comprehensive approach to treating ‍Alzheimer’s that involves multiple approaches, ‍including ⁤a combination of treatments and lifestyle ⁤interventions that target multiple mechanisms.

Potential ⁤Limitations

Espay acknowledges that the study ⁤has limitations, including the lack of access⁤ to individual-level ⁣data. However, the results were still supportive of the hypothesis, and the researchers plan to study treatments that‍ directly increase ​Aβ42 levels without targeting amyloid.